1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Precision Oncology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Precision Oncology Market, by Product
8.1.1 Diagnostics
8.1.1.1. Market Revenue and Forecast
8.1.2. Therapeutics0
8.1.2.1. Market Revenue and Forecast
9.1. Precision Oncology Market, by Cancer Type
9.1.1. Breast cancer
9.1.1.1. Market Revenue and Forecast
9.1.2. Colorectal cancer
9.1.2.1. Market Revenue and Forecast
9.1.3. Lung cancer
9.1.3.1. Market Revenue and Forecast
9.1.4. Blood Cancer
9.1.4.1. Market Revenue and Forecast
9.1.5. Prostate Cancer
9.1.5.1. Market Revenue and Forecast
9.1.6. Others
9.1.6.1. Market Revenue and Forecast
10.1. Precision Oncology Market, by Cancer Type
10.1.1. Pharmaceutical & Biotechnology Companies
10.1.1.1. Market Revenue and Forecast
10.1.2. Hospitals & Diagnostic Laboratories
10.1.2.1. Market Revenue and Forecast
10.1.3. Healthcare Data Companies
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product
11.1.2. Market Revenue and Forecast, by Cancer Type
11.1.3. Market Revenue and Forecast, by Cancer Type
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product
11.1.4.2. Market Revenue and Forecast, by Cancer Type
11.1.4.3. Market Revenue and Forecast, by Cancer Type
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product
11.1.5.2. Market Revenue and Forecast, by Cancer Type
11.1.5.3. Market Revenue and Forecast, by Cancer Type
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product
11.2.2. Market Revenue and Forecast, by Cancer Type
11.2.3. Market Revenue and Forecast, by Cancer Type
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product
11.2.4.2. Market Revenue and Forecast, by Cancer Type
11.2.4.3. Market Revenue and Forecast, by Cancer Type
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product
11.2.5.2. Market Revenue and Forecast, by Cancer Type
11.2.5.3. Market Revenue and Forecast, by Cancer Type
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product
11.2.6.2. Market Revenue and Forecast, by Cancer Type
11.2.6.3. Market Revenue and Forecast, by Cancer Type
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product
11.2.7.2. Market Revenue and Forecast, by Cancer Type
11.2.7.3. Market Revenue and Forecast, by Cancer Type
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product
11.3.2. Market Revenue and Forecast, by Cancer Type
11.3.3. Market Revenue and Forecast, by Cancer Type
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product
11.3.4.2. Market Revenue and Forecast, by Cancer Type
11.3.4.3. Market Revenue and Forecast, by Cancer Type
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product
11.3.5.2. Market Revenue and Forecast, by Cancer Type
11.3.5.3. Market Revenue and Forecast, by Cancer Type
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product
11.3.6.2. Market Revenue and Forecast, by Cancer Type
11.3.6.3. Market Revenue and Forecast, by Cancer Type
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product
11.3.7.2. Market Revenue and Forecast, by Cancer Type
11.3.7.3. Market Revenue and Forecast, by Cancer Type
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product
11.4.2. Market Revenue and Forecast, by Cancer Type
11.4.3. Market Revenue and Forecast, by Cancer Type
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product
11.4.4.2. Market Revenue and Forecast, by Cancer Type
11.4.4.3. Market Revenue and Forecast, by Cancer Type
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product
11.4.5.2. Market Revenue and Forecast, by Cancer Type
11.4.5.3. Market Revenue and Forecast, by Cancer Type
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product
11.4.6.2. Market Revenue and Forecast, by Cancer Type
11.4.6.3. Market Revenue and Forecast, by Cancer Type
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product
11.4.7.2. Market Revenue and Forecast, by Cancer Type
11.4.7.3. Market Revenue and Forecast, by Cancer Type
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product
11.5.2. Market Revenue and Forecast, by Cancer Type
11.5.3. Market Revenue and Forecast, by Cancer Type
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product
11.5.4.2. Market Revenue and Forecast, by Cancer Type
11.5.4.3. Market Revenue and Forecast, by Cancer Type
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product
11.5.5.2. Market Revenue and Forecast, by Cancer Type
11.5.5.3. Market Revenue and Forecast, by Cancer Type
12.1. Thermo Fisher Scientific, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Invitae Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Illumina, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Myriad Genetics, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AstraZeneca
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Rain Oncology Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Strata Oncology, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Repare Therapeutics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Relay Therapeutics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Exscientia
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
